Cargando…

Is adjuvant chemotherapy necessary in pT1N1 gastric cancer?

BACKGROUND: Due to a lack of consensus on adjuvant treatments for pT1N1 gastric cancer, surgeons face a dilemma when deciding treatments for patients with pT1N1 gastric cancer after gastrectomy. The objective of this study was to determine survival benefits of adjuvant chemotherapy and risk factors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Hyun Beak, An, Ji Yeong, Lee, Seung Hyoung, Choi, Yoon Young, Kim, Jong Won, Sohn, Soo Sang, Noh, Sung Hoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401346/ https://www.ncbi.nlm.nih.gov/pubmed/28431518 http://dx.doi.org/10.1186/s12885-017-3265-x

Ejemplares similares

Chemoresponse after non-curative gastrectomy for M1 gastric cancer
por: Shin, Hyun Beak, et al.
Publicado: (2015)

Is adjuvant chemotherapy necessary for early gastric cancer?
por: Mei, Yu, et al.
Publicado: (2022)

Actual compliance to adjuvant chemotherapy in gastric cancer
por: Kim, Dong-Wook, et al.
Publicado: (2019)

Single patient classifier as a prognostic biomarker in pT1N1 gastric cancer: Results from two large Korean cohorts
por: Choi, Yoon Young, et al.
Publicado: (2021)

The Effectiveness of Postoperative Chemotherapy on pT1bN0 and pT2N0 Gastric Cancer Patients with Risk Factors: An International Dual-Center Analysis
por: Yang, Kun, et al.
Publicado: (2021)

Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study
por: Gori, Stefania, et al.
Publicado: (2012)

Is adjuvant chemotherapy necessary in older patients with breast cancer?
por: Morita, Midori, et al.
Publicado: (2022)

The Assessment of the Oncological Safety Margin of Insufficient Lymph Node Dissection in pT2 (pm) Gastric Cancer
por: Choi, Yoon Young, et al.
Publicado: (2014)

Update of Adjuvant Chemotherapy for Resected Gastric Cancer
por: Oh, Sang Cheul
Publicado: (2012)

Is adjuvant chemotherapy necessary for patients with microinvasive breast cancer after surgery?
por: Niu, Hai-Fei, et al.
Publicado: (2016)

PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer
por: Kang, Yoon-Koo, et al.
Publicado: (2021)

Pathologic and Oncologic Outcomes in Locally Advanced Gastric Cancer with Neoadjuvant Chemotherapy or Chemoradiotherapy
por: An, Ji Yeong, et al.
Publicado: (2013)

Is Adjuvant Chemotherapy Beneficial to All Patients With pT3N0M0 Stage Gastric Cancer?
por: Huang, Jiao-Bao, et al.
Publicado: (2021)

Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial
por: Kim, Youjin, et al.
Publicado: (2018)

Is endoscopic surveillance necessary for patients who undergo total gastrectomy for gastric cancer?
por: Park, Sung Jae, et al.
Publicado: (2018)

Risk Factors for Discontinuation of S-1 Adjuvant Chemotherapy for Gastric Cancer
por: Kawazoe, Hitoshi, et al.
Publicado: (2015)

Silencing of peroxiredoxin II by promoter methylation is necessary for the survival and migration of gastric cancer cells
por: Hong, Soo Hyun, et al.
Publicado: (2018)

Decision-making of adjuvant therapy in pT1N1M0 gastric cancer: Should radiotherapy be added to chemotherapy? A propensity score-matched analysis
por: Pan, Siwei, et al.
Publicado: (2021)

Adjuvant Chemotherapy in pT2N0M0 Gastric Cancer: Findings From a Retrospective Study
por: Mei, Yu, et al.
Publicado: (2022)

Impact of Intratumoral Expression Levels of Fluoropyrimidine-Metabolizing Enzymes on Treatment Outcomes of Adjuvant S-1 Therapy in Gastric Cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2015)

Efficacy of S-1 or Capecitabine Plus Oxaliplatin Adjuvant Chemotherapy for Stage II or III Gastric Cancer after Curative Gastrectomy: A Systematic Review and Meta-Analysis
por: Jeong, Sang-Ho, et al.
Publicado: (2022)

Adjuvant Chemotherapy in Microsatellite Instability–High Gastric Cancer
por: Kim, Jin Won, et al.
Publicado: (2020)

ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy
por: Sun, Jong-Mu, et al.
Publicado: (2012)

Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1
por: Hisashige, Akinori, et al.
Publicado: (2013)

Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer
por: YANG, LIN, et al.
Publicado: (2015)

Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling
por: Xylinas, E, et al.
Publicado: (2012)

Updated Adjuvant Chemotherapy for Gastric Cancer
por: Takayama, Toshizo, et al.
Publicado: (2023)

Metastatic lymph node in gastric cancer; Is it a real distant metastasis?
por: Lim, Do Hyoung, et al.
Publicado: (2010)

Benefit of Adjuvant Traditional Herbal Medicine With Chemotherapy for Resectable Gastric Cancer
por: Lee, Yu Kyung, et al.
Publicado: (2018)

Impact of adjuvant chemotherapy for gliomatosis cerebri
por: Kong, Doo-Sik, et al.
Publicado: (2010)

Difficulty of predicting the presence of lymph node metastases in patients with clinical early stage gastric cancer: a case control study
por: Nakagawa, Masatoshi, et al.
Publicado: (2015)

Risk Factors and Tumor Recurrence in pT1N0M0 Gastric Cancer after Surgical Treatment
por: Choi, Hee Jun, et al.
Publicado: (2016)

Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial
por: Choi, Wonyoung, et al.
Publicado: (2020)

Current status of adjuvant chemotherapy for gastric cancer
por: Kim, In-Hwan
Publicado: (2019)

Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2022)

S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
por: Lee, Choong-kun, et al.
Publicado: (2019)

Effect of Early Adjuvant Chemotherapy on Survival of Advanced Gastric Cancer Patients: a Propensity Score-matched Analysis
por: Lee, Yoontaek, et al.
Publicado: (2018)

Benefits of adjuvant treatment including trastuzumab in HER2-positive pT1a-bN0M0 breast cancer: a systematic review and meta-analysis
por: Lee, Hye Yoon, et al.
Publicado: (2020)

Optimal time interval from surgery to adjuvant chemotherapy in gastric cancer
por: Ahn, Geon Tae, et al.
Publicado: (2020)

Effects of Continuing Adjuvant S-1 for 1 Year on the Prognosis of Gastric Cancer Patients: Results from a Prospective Single Center Study
por: Eun, Hasu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7itg2v3jo3bb57l74gma6pm02m